Abstract:OBJECTIVE:To compare the transcatheter arterial chemoembolization (TACE) alone or plus radiofrequency ablation (RFA) in the treatment of single branch portal vein tumor thrombus(PVTT)in patients with hepatocellular carcinoma (HCC) so as to evaluate the safety, control rate, prognostic factors and overall survival. METHODS:From January 2004 to December 2007, 50 HCC patients (< 5 cm in diameter and 3 parenchymal lesions) with concurrent PVTT were enrolled and treated by TACE alone or TACE plus RFA randomly (TACE, n = 25; TACE-RFA, n = 25). In TACE group, the intra-hepatic lesions received TACE sequentially with RFA; in TACE-RFA group, PVTT and intra-hepatic lesions were treated with TACE sequentially with RFA separately. Strict follow-up was conducted by computed tomography and alpha-fetoprotein (AFP) assay. The survival time was analyzed by the Kaplan-Meier method and Cox regression analysis was performed to evaluate the prognostic factors. RESULTS:Of all 50 HCC patients with single branch PVTT with TACE or RFA, 47 patients (TACE, n = 24; TACE-RFA, n = 23) received all the scheduled procedures and completed the follow-up. Two patients (8.3%) in TACE group had liver dysfunction versus none in TACE-RFA group, 2 patients (8.7%) developed bile duct injury in TACE-RFA group related with the RFA procedure. The OR (overall response) for PVTT was 54.2% (complete response (CR) 8.3%, partial response (PR) 45.8%) in TACE group while 87.0% (CR 60.9%, PR 26.1%) in TACE-RFA group during the follow-up. From the definite diagnosis of HCC, the median survival was 8 months. And the 1-, 2- & 3-year survival rates were 33.3%, 12.5%, 8.3% in TACE group. And 26 months, 65.2%, 47.8%, 30.4% in TACE-RFA group respectively. The difference between two groups was significant. From the definite diagnosis of PVTT, the respective data were 7 months, 12.5% and 4.2%, 0 in TACE group versus 22 months, 52.2%, 34.8%, and 8.7% in TACE-RFA group with a significant P value. In multivariate analysis, only therapy (TACE or TACE-RFA) showed a protective value (hazard rate 0.430 vs 0.345, P < 0.05). Survival was not correlated with age, intra-hepatic tumor status, liver functions and AFP level for all patients. CONCLUSION:RFA is both safe and efficacious to prolong survival in the treatment of single branch PVTT plus TACE in selected HCC patients. It may provide rationales for further studies of evaluating the outcome of RFA plus other therapies in the treatment of HCC with single branch PVTT.

Survival Benefit of Hepatic Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Systematic Review and Meta-Analysis.

Hepatic Resection Versus Transcatheter Arterial Chemoembolization for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Comparative Efficacy of Treatment Strategies for Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis.

A Systematic Review Comparing Outcomes of Surgical Resection and Non-Surgical Treatments for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis

Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Meta-Analysis

Is Surgical Resection Justified For Hepatocellular Carcinoma With Portal Vein Tumor Thrombus? A Systematic Review And Meta-Analysis

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study

Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: a Meta-Analysis.

Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis

The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Transcatheter Arterial Chemoembolization (TACE) Versus Hepatectomy in Hepatocellular Carcinoma with Macrovascular Invasion: a Meta-Analysis of 1683 Patients.

Efficacy of Postoperative Transarterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis - A Randomized Study

Survival Benefits from Adjuvant Transcatheter Arterial Chemoembolization in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis

Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

TACE with Portal Vein Radioactive Seeds for HCC with Portal Vein Tumor Thrombus: a Meta-Analysis

Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis

Postoperative Adjuvant Chemo (embolization) Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Who Can Benefit from Adjuvant Transcatheter Arterial Chemoembolization after Surgical Resection of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis

[Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].